Macrosalb Medi-Radiopharma (Macrosalb (99mtc))

Macrosalb contains technetium‑99m labeled macroaggregated albumin particles. After intravenous injection, the particles become temporarily trapped in the pulmonary capillaries, emitting gamma radiation that a gamma camera detects, producing a visual map of regional lung blood flow.

The administered activity of Macrosalb is determined by the prescribing physician or nuclear medicine specialist based on the specific imaging protocol, patient size, and regulatory guidelines. The exact dose is not standardized and must be individualized.

Safety data for Macrosalb in pregnancy and lactation are limited. It should be avoided unless the diagnostic benefit outweighs potential fetal or infant radiation exposure. Clinicians should discuss risks with the patient and consider alternative imaging methods when possible.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Macrosalb (technetium‑99m macroaggregated albumin) is the most widely used perfusion agent because of its favorable particle size, rapid lung uptake, and short half‑life. Alternatives such as xenon gas or other radiolabeled particles exist, but they may require special equipment, have different imaging characteristics, or provide less consistent capillary lodging.

Macrosalb kits should be stored at ambient temperature, preferably below 25 °C, protected from moisture and light. Keep the kit in its original sealed container until preparation, and use it before the expiration date indicated on the label.

Macrosalb is prepared according to the kit instructions and administered intravenously by a qualified healthcare professional. The injection is typically performed as a rapid bolus, followed by immediate imaging with a gamma camera to capture lung perfusion data.

The most serious risks include severe allergic reactions such as anaphylaxis, rare radiation‑induced tissue injury, and hemodynamic disturbances like hypotension or arrhythmias, particularly in patients with underlying cardiovascular disease.

Macrosalb should not be administered to patients with known hypersensitivity to albumin, technetium‑99m, or any kit components. It is also contraindicated in pregnant women unless the diagnostic benefit justifies the potential fetal radiation exposure, and in patients with severe uncontrolled cardiopulmonary conditions where perfusion imaging may be unsafe.